Inventor · disambiguated record
Andrew A. Young
Also filed as: YOUNG ANDREW · YOUNG ANDREW A
69 granted patents·34 pending applications·3,089 citations·filing 1991–2024
99Inventor score
Files withAMYLIN PHARMACEUTICALS INC47SATIOGEN PHARMACEUTICALS INC8AMYLIN PHARMACEUTICALS LLC7YOUNG ANDREW A7INTARCIA THERAPEUTICS INC6
Top patents by PatentIndex Score
103 records- 0199US6924264B1Modified exendins and exendin agonistsAMYLIN PHARMACEUTICALS INC·Filed 2000·Granted Aug 2, 2005·169 cites·23 claims
- 0298US7928065B2Methods of treatment using exendin peptides or GLP-1 peptidesAMYLIN PHARMACEUTICALS INC·Filed 2008·Granted Apr 19, 2011·63 cites·45 claims
- 0398US7691963B2Exendins and exendin agonists modified with polyamino acidsAMYLIN PHARMACEUTICALS INC·Filed 2008·Granted Apr 6, 2010·48 cites·20 claims
- 0498US7419952B2Use of exendins and agonists thereof to treat diabetesAMYLIN PHARMACEUTICALS INC·Filed 2006·Granted Sep 2, 2008·53 cites·20 claims
- 0598US7153825B2Methods for glucagon suppression using modified exendinsAMYLIN PHARMACEUTICALS INC·Filed 2005·Granted Dec 26, 2006·111 cites·35 claims
- 0698US6872700B1Methods for glucagon suppressionAMYLIN PHARMACEUTICALS INC·Filed 2000·Granted Mar 29, 2005·184 cites·24 claims
- 0798US6858576B1Methods for regulating gastrointestinal motilityAMYLIN PHARMACEUTICALS INC·Filed 1997·Granted Feb 22, 2005·211 cites·22 claims
- 0897US8445647B2Modified exendins and exendin agonistsPRICKETT KATHRYN S·Filed 2011·Granted May 21, 2013·51 cites·6 claims
- 0997US8288338B2Exendin and exendin agonists for eating disordersYOUNG ANDREW A·Filed 2010·Granted Oct 16, 2012·62 cites·20 claims
- 1097US8026210B2Exendins and exendin agonist analogs to regulate gastrointestinal motilityAMYLIN PHARMACEUTICALS INC·Filed 2009·Granted Sep 27, 2011·43 cites·21 claims
- 1197US7741269B2Exendins and exendin agonists for weight reduction and obesityAMYLIN PHARMACEUTICALS INC·Filed 2004·Granted Jun 22, 2010·88 cites·44 claims
- 1297US7683030B2Methods of treating diabetes with albumin-conjugated exendin peptidesAMYLIN PHARMACEUTICALS INC·Filed 2008·Granted Mar 23, 2010·42 cites·15 claims
- 1397US7608692B2Exendins and exendin agonists modified with albuminAMYLIN PHARMACEUTICALS INC·Filed 2008·Granted Oct 27, 2009·43 cites·12 claims
- 1497US7521423B2Exendin pharmaceutical compositionsAMYLIN PHARMACEUTICALS INC·Filed 2004·Granted Apr 21, 2009·96 cites·32 claims
- 1597US7407932B2Methods for glucagon suppression using modified exendinsAMYLIN PHARMACEUTICALS INC·Filed 2006·Granted Aug 5, 2008·41 cites·7 claims
- 1697US7297761B2Pharmaceutical compositions containing exendinsAMYLIN PHARMACEUTICALS INC·Filed 2004·Granted Nov 20, 2007·114 cites·37 claims
- 1797US7138375B2Use of exendins and agonists thereof for lowering plasma lipidAMYLIN PHARMACEUTICALS INC·Filed 2004·Granted Nov 21, 2006·95 cites·20 claims
- 1897US7115569B2Exendins, exendin agonists, and methods for their useAMYLIN PHARMACEUTICALS INC·Filed 2004·Granted Oct 3, 2006·114 cites·60 claims
- 1997US6902744B1Exendin agonist formulations and methods of administration thereofAMYLIN PHARMACEUTICALS INC·Filed 2000·Granted Jun 7, 2005·180 cites·42 claims
- 2096US8263545B2GIP analog and hybrid polypeptides with selectable propertiesLEVY ODILE ESTHER·Filed 2007·Granted Sep 11, 2012·62 cites·3 claims
- 2196US8057822B2Modified exendins and exendin agonistsPRICKETT KATHRYN S·Filed 2005·Granted Nov 15, 2011·42 cites·25 claims
- 2296US7700549B2Exendin agonist analogs to treat diabetesAMYLIN PHARMACEUTICALS INC·Filed 2008·Granted Apr 20, 2010·43 cites·18 claims
- 2396US7442680B2Inotropic and diuretic effects of GLP-1 and GLP-1 agonistsAMYLIN PHARMACEUTICALS INC·Filed 2003·Granted Oct 28, 2008·66 cites·16 claims
- 2496US6703359B1Inotropic and diuretic effects of exendin and GLP-1AMYLIN PHARMACEUTICALS INC·Filed 1999·Granted Mar 9, 2004·160 cites·42 claims
- 2595US9339480B2Bile acid recycling inhibitors for treatment of obesity and diabetesYOUNG ANDREW A·Filed 2009·Granted May 17, 2016·38 cites·23 claims
- 2695US8497240B2DPP-IV resistant GIP hybrid polypeptides with selectable propertiesLEVY ODILE ESTHER·Filed 2007·Granted Jul 30, 2013·25 cites·11 claims
- 2795US7399489B2Exendin analog formulationsAMYLIN PHARMACEUTICALS INC·Filed 2005·Granted Jul 15, 2008·40 cites·36 claims
- 2894US5739106AAppetite regulating compositionsFiled 1995·Granted Apr 14, 1998·134 cites·85 claims
- 2993US6114304AMethods for regulating gastrointestinal motilityAMYLIN PHARMACEUTICALS INC·Filed 1994·Granted Sep 5, 2000·103 cites·35 claims
- 3092US7960341B2Methods and compositions for treating polycystic ovary syndromeAMYLIN PHARMACEUTICALS INC·Filed 2006·Granted Jun 14, 2011·16 cites·10 claims
- 3192US7105490B2Methods and compositions for treating polycystic ovary syndromeAMYLIN PHARMACEUTICALS INC·Filed 2003·Granted Sep 12, 2006·35 cites·71 claims
- 3291US7906146B2Lyophilized formulations of exendins and exendin agonist analogsAMYLIN PHARMACEUTICALS INC·Filed 2009·Granted Mar 15, 2011·14 cites·20 claims
- 3391US5234906AHyperglycemic compositionsAMYLIN PHARMACEUTICALS INC·Filed 1991·Granted Aug 10, 1993·125 cites·24 claims
- 3490US11840559B2Glucagon-receptor selective polypeptides and methods of use thereofINTARCIA THERAPEUTICS INC·Filed 2021·Granted Dec 12, 2023·1 cites·19 claims
- 3590US8404637B2GIP analog and hybrid polypeptides with selectable propertiesLEVY ODILE ESTHER·Filed 2006·Granted Mar 26, 2013·16 cites·12 claims
- 3689US7671023B2Amylin agonist for treating depression, anxiety disorder and schizophreniaAMYLIN PHARMACEUTICALS INC·Filed 2006·Granted Mar 2, 2010·8 cites·3 claims
- 3788US9345715B2Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereofSATIOGEN PHARMACEUTICALS INC·Filed 2012·Granted May 24, 2016·10 cites·11 claims
- 3888US8318663B2Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agentYOUNG ANDREW A·Filed 2009·Granted Nov 27, 2012·9 cites·17 claims
- 3987US11214607B2Glucagon-receptor selective polypeptides and methods of use thereofINTARCIA THERAPEUTICS INC·Filed 2019·Granted Jan 4, 2022·3 cites·20 claims
- 4087US8273713B2Methods of treating obesity using PYY[3-36]PITTNER RICHARD A·Filed 2001·Granted Sep 25, 2012·37 cites·7 claims
- 4186US11260053B2Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditionsSATIOGEN PHARMACEUTICALS INC·Filed 2019·Granted Mar 1, 2022·1 cites·21 claims
- 4284US10501517B2Glucagon-receptor selective polypeptides and methods of use thereofINTARCIA THERAPEUTICS INC·Filed 2017·Granted Dec 10, 2019·4 cites·61 claims
- 4383US11654183B2Methods comprising continuous administration of exenatide and co-administration of a drugINTARCIA THERAPEUTICS INC·Filed 2020·Granted May 23, 2023·1 cites·14 claims
- 4480US10555950B2Bile acid recycling inhibitors for treatment of obesity and diabetesSATIOGEN PHARMACEUTICALS INC·Filed 2016·Granted Feb 11, 2020·2 cites·6 claims
- 4580US10251880B2Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditionsSATIOGEN PHARMACEUTICALS INC·Filed 2014·Granted Apr 9, 2019·3 cites·12 claims
- 4680US2024239861A1Glucagon-receptor selective polypeptides and methods of use thereofI2O THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4779US6602694B1Uncoupling protein 4 (UCP-4)AMYLIN PHARMACEUTICALS INC·Filed 1999·Granted Aug 5, 2003·37 cites·5 claims
- 4878US10188646B2Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditionsGEDULIN BRONISLAVA·Filed 2012·Granted Jan 29, 2019·3 cites·15 claims
- 4977US8951962B2Modified exendins and exendin agonistsAMYLIN PHARMACEUTICALS LLC·Filed 2013·Granted Feb 10, 2015·4 cites·12 claims
- 5077US5321008AMethods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditionsAMYLIN PHARMACEUTICALS INC·Filed 1991·Granted Jun 14, 1994·43 cites·14 claims
Showing the top 50 of 103 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Andrew A. Young files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →